The US Food and Drug Administration (FDA) has approved secukinumab (Cosentyx, Novartis) for the treatment of active enthesitis-related arthritis (ERA) in children and adolescents age 4 years and older ...

Persistent joint pain in children may signal juvenile arthritis, not just growing pains. Early identification of this ...

A new study by researchers from the University of Birmingham, UCL, Great Ormond Street Hospital and Birmingham Children's Hospital has revealed important clues into what is driving disease in children ...

Arthritis is often associated with older age, but it also affects children. One of the most common forms is juvenile idiopathic arthritis (JIA), an inflammatory condition that causes persistent joint ...

JIA is the most common chronic inflammatory arthritis in children, affecting approximately 1 in every 1,000 children ...

The US Food and Drug Administration (FDA) has approved an expanded indication for abatacept (Orencia) for treatment of psoriatic arthritis (PsA) in pediatric patients 2 years of age and older.

The approval is supported by evidence from adequate and well-controlled studies of Stelara. The Food and Drug Administration (FDA) has expanded the approval of Stelara ® (ustekinumab) to include ...

If your child consistently wakes up with stiff joints for more than 30 minutes, it could indicate a medical condition.

In a recent Morbidity and Mortality Weekly Report (MMWR) published by the United States Centers for Disease Control and Prevention (CDC), researchers combine survey data from the National Survey of ...

TREMFYA® is now approved for pediatric patients living with moderate to severe plaque psoriasis, who are candidates for systemic therapy or phototherapy, and active psoriatic arthritis in children six ...

Please provide your email address to receive an email when new articles are posted on . Children with spondyloarthritis and polyarticular arthritis demonstrate greater internalized disturbances and ...